Publications
The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release
The First-in-Class Anti-Staphylococcal Antibiotic Afabicin Desphosphono is Not Associated With Clostridioides difficile Infection in an in vitro Human Gut Model
Assessment of Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment for the Anti-Staphylococcal Antibiotic Afabicin
Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal…
Debio 0123 + Carboplatin for Patients with Advanced Solid Tumors: Safety, Preliminary Efficacy and Determination of Recommended Phase 2 Dose
Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin and etoposide in patients with small cell lung cancer that…